NCT01518881View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion

PHASE1TerminatedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Ebola Virus Infection
Interventions
DRUG

TKM-100201

IV Infusion

DRUG

Placebo

IV infusion

Trial Locations (1)

58104

Cetero Research, Fargo

Sponsors
All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Arbutus Biopharma Corporation

INDUSTRY

NCT01518881 - Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study of Intravenous (IV) TKM-100201 Infusion | Biotech Hunter | Biotech Hunter